


**AMENDMENTS TO THE CLAIMS**


1-6. Canceled.

7. (Currently Amended) A method of inducing death in tumor cells, comprising contacting the cells with a compound selected from the group consisting of:

(a) a compound having the following formula:




(b) a compound having the following formula:




~~(c) a compound that is an analog of (a) and is selectively toxic to tumor cells.~~

8. (Currently Amended) A method of inducing death in cells in which the RAS pathway is activated, comprising contacting the cells with a compound selected from the group consisting of:

(a) a compound having the following formula:




(b) a compound having the following formula:



~~(c) a compound that is an analog of (a) and is selectively toxic to cells in which the RAS pathway is activated.~~


9. (Currently Amended) A method of inducing death in human cells expressing SV40 small T oncoprotein and oncogenic HRAS, comprising contacting the human cells with a compound selected from the group consisting of:

(a) a compound having the following formula:




; and

(b) a compound having the following formula:



(c) ~~a compound that is an analog of (a) and is selectively toxic to human cells expressing SV40 small T oncoprotein and oncogenic HRAS.~~


10. (Currently Amended) A pharmaceutical ~~pharmaceutical~~ composition comprising a pharmaceutically acceptable carrier and a compound having the following formula:



~~or an analog thereof~~, which is selectively toxic to engineered human tumorigenic cells.

11. Canceled

12. (Currently Amended) A ~~pharmaceutical pharmaceutical~~ composition comprising a pharmaceutically acceptable carrier and a compound having the following formula:



~~or an analog thereof~~, which is selectively toxic to engineered human tumorigenic cells.

13-66. Canceled.